USF Scholars in Patient-Oriented Research (SPOR)

这是一项针对南佛罗里达大学以患者为中心的研究(SPOR)学者项目的提案 ‘_(美国联邦)。在过去的十年里，加州大学朝着成为一所主要研究型大学的目标迈进了一大步。 将外部研究资金从每年不到2500万美元增加到近2.5亿美元。其中一半以上的资金来自 健康科学中心(HSC)。目前，这些资金中约有一半来自行业赞助的临床治疗试验， 另一半的资金用于研究人员发起的研究。因此，USF HSC的优先事项是 专注于培养一支强大的教职员工队伍，他们拥有以患者为导向的研究专业知识，并有能力 除了接受同行审查的外部资金外，我们显然需要提高专科研究金的水平 培训计划，以培训越来越多的次专科研究员成为学术、临床和翻译人员 研究人员。K30赠款是启动这些努力的理想机制。幸运的是，在我们机构内 莫菲特癌症中心是美国国家癌症研究所指定的综合性癌症中心，在建立 临床研究计划，为初级教员提供的临床和翻译研究指导计划，以及NCI K12- 资助临床和转化性研究培训计划。拟议的计划将利用这些专业知识 在莫菲特开发的，以及在USF的许多较小的临床研究专业领域，以培训初级教员和 伙计们。Spor项目将使你获得硕士学位。它将由课堂核心和基于网络的教学组成 教学和有指导的临床研究项目。许多课程已经存在，其他课程将从 目前的课程，而一些课程将专门为Spor计划实习生设计。必修课将 包括研究和职业道德；专家精神；科学写作；临床研究多样性；细胞原理 生物学、生理学、药理学和分子生物学；生物统计学和信息学；成功的基础 以病人为中心的研究。将提供三条途径：治疗性临床研究人员(临床试验设计； 阶段11临床试验设计、进行、分析和资助)、基于人群的研究(流行病学和试验 设计)，人类疾病的机制(代谢的分子基础，临床药理学，生物信息学)。一篇论文 或基于导师研究的同行评议出版物(S)将是必需的。执行委员会将监督 该方案将设有小组委员会，负责(1)学员遴选、(2)导师遴选(3)课程(4)评估 流程；以及(5)SPOR计划的整体进度。过程评估将基于对课程的评估， 有指导的研究，以及整个计划。评估的主要长期成果将包括 学术岗位受训人员、从事生产性临床研究(手稿和摘要)的受训人员和受训人员 与国家鹿审查资助的临床和翻译研究Droqram。

This is a proposal is for a Scholars in Patient-Oriented Research (SPOR) Program at the University of South Florida '_(USF). USF has made major strides over the past decade toward the goal of becoming a major research university increasing external research funding from less than $25M to nearly $250M annually. Over half of this funding is in the Health Sciences Center (HSC). About half of this funding currently is from industry-sponsored clinical therapeutic trials, and with the other half of the funding is for investigator-initiated research. Thus, it is a priority of the USF HSC to concentrate on developing a strong cadre of faculty members with expertise in patient-oriented research that is capable of receiving peer-reviewed external funding, in addition, we have a clear need to upgrade the subspecialty fellowship training programs to train increasing numbers of subspeciaity fellows to become academic clinical and translational researchers. The K30 grant is an ideal mechanism for jumpstarting these efforts. Fortunately, within our institution the Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center, has done an outstanding job of building a clinical research program, a clinical and translational research mentoring program for junior faculty, and a NCI K12- funded Clinical and Translational Research Training program. The proposed program will utilize the expertise developed at Moffitt, as well as many of the smaller foci of clinical research expertise at USF, to train junior faculty and fellows. The SPOR Program will lead to a Masters degree. It will consist of a core of classroom and web-based didactic teaching and a mentored clinical research project. Many of the courses already exist, and others will be derived from current courses, whereas some courses will be designed specifically for SPOR Program trainees. Required courses will include research and professional ethics; grantsmanship; scientific writing; diversity in clinical research; principles of cell biology, physiology, pharmacology, and molecular biology; biostatistics and informatics; fundamentals of successful patient-oriented research. There will be three tracks available: therapeutic clinical researchers (clinical trial design; Phase !/11clinical trial design, conduct, analysis and funding), population-based research (epidemiology and trial design), mechanisms of human disease (molecular basis of metabolism, clinical pharmacology, bioinformatics). A thesis or peer-reviewed publication(s) based on mentored research will be required. The executive committee will oversee the Program and will have subcommittees for (1) trainee selection, (2) mentor selection (3) curriculum (4) evaluation processes; and (5) overall SPOR Program progress. Process assessment will be based on evaluations of courses, mentored research, and the Program overall. The major long-term outcomes evaluated will include the number of trainees in academic positions, trainees doing productive clinical research (manuscripts and abstracts), and trainees with national Deer-review funded clinical and translational research Droqrams.